CytoPak GMP Human IL-15 ProteinDMF

  • No equivalent PG product available.
Customer Reviews
Cat. No. / Size
Price
Qty
CytoPak
GMP-L15H13GB01-10ug
$370.00
GMP lyophilized
GMP-L15H13-50ug
$855.00
GMP-L15H13-1mg (50ug X 20)
$7325.00
GMP-L15H13-10mg (50ug X 200)
$51275.00
CytoPak
GMP-L15H13GB02-50ug
Inquiry
ETA of in-stock products:2 business days

Product Details

  • IL-15 PRODUCT SHOW

    CytoPak GMP Human IL-15 Protein is packaged in sterile closed containers that can be readily incorporated into ex vivo clinical production processes. The bag utilizes medical grade multilayer film with two weldable options. The outlet weldable tube contains a proximal TPE section (1/8’’ ID x 1/4’’ OD) and a distal PVC section (3/32’’ ID x 5/32’’ OD). The liquid state and closed-system packaging of CytoPak GMP Human IL-15 Protein can be directly welded to GMP media bags resulting in safety and user-friendliness by bypassing the reconstitution step during manufacture.

  • GMP Platform Advantages

    1. Quality Assurance: Global QMS with comprehensive and stringent QC release criteria.
    2. End-to-End GMP Compliance: Full manufacturing and QC under a cGMP system.
    3. Comprehensive Control of Adventitious Agents: Stringent biosafety from cell banks to final release.
    4. Comprehensive Regulatory Support: Includes RSF and DMF to meet global requirements.
    5. Resilient Supply Chain: Intelligent modular facilities ensure a stable global supply.
    6. Professional Support: Extensive manufacturing and application expertise to accelerate development.
  • Source

    CytoPak GMP Human IL-15 Protein (GMP-L15H13GB01) is expressed from E. coli cells. It contains AA Asn 49 - Ser 162 (Accession # P40933-1).

  • Molecular Characterization

    IL-15 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries no "tag".

    The protein has a calculated MW of 12.9 kDa. The protein migrates as 13 kDa±3 kDa under reducing (R) condition (SDS-PAGE).

  • N-terminal Sequence Analysis

    Met-Asn-Trp-Val-Asn-Val-Ile-Ser-Asp-Leu-Lys-Lys-Ile-Glu-Asp
    (Routinely tested)

  • Endotoxin

    Less than 1.0 EU/mL, tested by the LAL method in compliance with USP <85> and Ph. Eur. 2.6.14.

  • Host Cell Protein

    <0.5 ng/µg of protein tested by ELISA.

  • Host Cell DNA

    <0.02 ng/μg of protein tested by qPCR.

  • Sterility

    Sterility testing was performed using the membrane filtration method in compliance with USP <71> and Ph. Eur. 2.6.1.

  • Mycoplasma

    Negative

  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Supplied as 0.2 μm filtered solution in PBS, rHSA, pH7.4.

    Contact us for customized product form or formulation.

  • Shipping

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • Storage

    Upon receipt, store it immediately at -20°C or lower for long term storage.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. Can be stored up to 24 months at -20°C;
    2. Can be stored up to 2 weeks at 2-8°C.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    IL-15 SDS-PAGE

    CytoPak GMP Human IL-15 Protein on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • Mass Spectrometry

     IL-15 MASS_SPECTROMETRY

    ESI-MS analysis of CytoPak GMP Human IL-15 Protein (Cat. No. GMP-L15H13GB01), the labeled peak at 12892.3 Da corresponds to the calculated molecular mass 12904.69 Da (Routinely tested).

  • Bioactivity-CELL BASE

     IL-15 CELL

    CytoPak GMP Human IL-15 Protein (Cat. No. GMP-L15H13GB01) stimulates proliferation of CTLL-2 cells. The specific activity of CytoPak GMP Human IL-15 Protein is > 8.00ⅹ10^6 IU/mg, which is calibrated against human IL-15 WHO International Standard (NIBSC code: 95/554) (QC tested).

    Protocol
  • Consistent Concentration: CytoPak vs Lyophilized

     IL-15 CONSISTENT CONCENTRATION

    CytoPak GMP Human IL-15 Protein (Cat. No. GMP-L15H13GB01) and lyophilized IL-15 (Cat. No. GMP-L15H13) were added to CelThera™ GMP T Cell Expansion Medium in parallel. After cytokine addition, the concentration of IL-15 was determined by ELISA. Data is the average of 4 independent experiments with error bars ±SD.

  • Bioactivity-Stability

     IL-15 STABILITY

    Cell-based assay demonstrates that CytoPak GMP Human IL-15 Protein (Cat. No. GMP-L15H13GB01) is stable at 37°C for 15 days.

  •  IL-15 STABILITY

    Cell-based assay demonstrates that CytoPak GMP Human IL-15 Protein (Cat. No. GMP-L15H13GB01) is stable after 3 freeze-thaw cycles.

Customer Reviews
Writing Reviews

Background

Interleukin 15 is also known as IL15, IL-15, and is a cytokine with structural similarity to IL-2. Like IL-2, IL-15 binds to and signals through the IL-2/IL-15 beta chain (CD122) and the common gamma chain (gamma-C, CD132). IL-15 is secreted by mononuclear phagocytes (and some other cells) following infection by virus(es). This cytokine induces cell proliferation of natural killer cells; cells of the innate immune system whose principal role is to kill virally infected cells. Interleukin 15 (IL-15) regulates T and natural killer (NK) cell activation and proliferation. Survival signals that maintain memory T cells in the absence of antigen are provided by IL-15. This cytokine is also implicated in NK cell development. In rodent lymphocytes, IL-15 prevents apoptosis by inducing an apoptosis inhibitor, BCL2L1/BCL-x(L). IL-15 has been shown to enhance the anti-tumor immunity of CD8+ T cells in pre-clinical models. A phase I clinical trial to evaluate the safety, dosing, and anti-tumor efficacy of IL-15 in patients with metastatic melanoma and renal cell carcinoma (kidney cancer) has begun to enroll patients at the National Institutes of Health.

Important Statement

  • MANUFACTURING SPECIFICATIONS

    ACROBiosystems GMP grade products are produced under a quality management system and in compliance with relevant guidelines: Ph. Eur General Chapter 5.2.12 Raw materials of biological origin for the production of cell-based and gene therapy medicinal products; USP<92>Growth Factors and Cytokines Used in Cell Therapy Manufacturing; USP<1043>Ancillary Materials for Cell, Gene, and Tissue-Engineered Products; ISO/TS 20399-1:2018, Biotechnology - Ancillary Materials Present During the Production of Cellular Therapeutic Products.

    ACROBiosystems Quality Management System Contents:

    1. GMP-certified facility (compliance with FDA cGMP, EMA GMP, ICH, ISO9001/13485/MDSAP, and certified by third-party SGS, UL, and RX360)
    2. Animal origin-free materials, equipments, and facilities
    3. Materials sourced only from approved suppliers
    4. ISO 5 cleanrooms and automatic filling equipment
    5. Professional quality personnel and training programs
    6. Validated analytical testing methods in accordance with the ICH guidelines
    7. Safety Testing (Sterility, Mycoplasma, etc): compliant with USP, EP, etc
    8. In-depth stability studies
    9. Fully batch production and control records
    10. Equipment maintenance and calibration

    Request For Regulatory Support Files (RSF)

    ACROBiosystems provide rigorous quality control tests (fully validated equipment, processes and test methods) on our GMP grade products to ensure that they meet stringent standards in terms of purity, safety, activity and inter-batch stability, and each bulk QC lot mainly contains the following specific information:

    1. SDS-PAGE
    2. Protein content
    3. Endotoxin level
    4. Residual Host Cell DNA content
    5. Residual Host Cell Protein content
    6. Biological activity analysis
    7. Microbial testing
    8. Mycoplasma testing
    9. In vitro virus assay
    10. Batch-to-batch consistency

  • ACROBIOSYSTEMS - LEGAL NOTICES FOR GMP GRADE PRODUCTS

    1. PRODUCT USE RESTRICTIONS & PROHIBITIONS

    • 1.1 ACROBiosystems ("ACRO") GMP grade products ("Products") are designed for research, manufacturing use or ex vivo use.
    • 1.2 Products are NOT intended for diagnostic purposes or for direct or indirect administration into humans.
    • 1.3 Purchaser shall not market, distribute, or resell Products obtained from ACRO without ACRO's prior written consent.

    2. REVERSE ENGINEERING PROHIBITED & CONFIDENTIALITY

    • 2.1 Purchaser shall not reverse-engineer, decompile, disassemble, sequence, analyze via bioinformatics, or otherwise attempt to discover the structure, sequence, composition, construction, manufacturing process, or any trade secret embodied in the Products. Purchaser shall not permit any third party to undertake such activities.
    • 2.2 All specifications, data, and know-how related to the Products provided by ACRO are ACRO's confidential information and shall be protected accordingly.

    3. LIMITED WARRANTY & DISCLAIMERS

    • 3.1 ACRO warrants solely that Products will conform to their published specifications when used under normal, specified laboratory/manufacturing conditions and within their labeled expiration date. THIS IS THE ONLY WARRANTY PROVIDED.
    • 3.2 Purchaser assumes ALL risk and responsibility for:
      (a) Determining the suitability of Products for Purchaser's intended application(s).
      (b) Obtaining any necessary regulatory approvals or intellectual property licenses for Purchaser's use.
      (c) Compliance with all applicable laws, regulations (including but not limited to cGMP/GLP where claimed), and industry standards.
      (d) Conducting all necessary quality control, safety, efficacy, and validation testing of Products within Purchaser's process or final product.
      (e) Proper storage, handling, and use of Products according to ACRO's instructions.
    • 3.3 ACRO EXPRESSLY DISCLAIMS ALL OTHER WARRANTIES, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE, INCLUDING BUT NOT LIMITED TO: (A) WARRANTIES OF MERCHANTABILITY; (B) WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE; (C) WARRANTIES OF NON-INFRINGEMENT; AND (D) WARRANTIES ARISING FROM COURSE OF DEALING OR USAGE OF TRADE.

    4. LIMITATION OF LIABILITY

    • IN NO EVENT SHALL ACRO, ITS AFFILIATES, OR SUPPLIERS BE LIABLE FOR ANY OF THE FOLLOWING, HOWSOEVER ARISING (WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, STATUTE, OR OTHERWISE):
      (a) LOST PROFITS, LOST REVENUE, LOST SAVINGS, LOSS OF USE, LOSS OF DATA, BUSINESS INTERRUPTION, OR ANY OTHER INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES.
      (b) ANY DIRECT DAMAGES, COSTS, OR EXPENSES EXCEEDING THE AMOUNT PAID BY PURCHASER FOR THE SPECIFIC PRODUCT(S) GIVING RISE TO THE CLAIM.
      (c) DAMAGES ARISING FROM: (i) MISUSE, ABUSE, OR UNAUTHORIZED MODIFICATION OF PRODUCTS; (ii) USE BEYOND THE EXPIRATION DATE; (iii) IMPROPER STORAGE OR HANDLING; (iv) ACCIDENTAL DAMAGE; (v) FAILURE TO CONDUCT ADEQUATE VALIDATION OR TESTING BY PURCHASER; (vi) INFRINGEMENT CLAIMS RELATED TO PURCHASER'S USE; OR (vii) THE COST OF PROCURING SUBSTITUTE GOODS OR SERVICES.
      (d) ANY PERSONAL INJURY, DEATH, OR DAMAGE TO TANGIBLE PROPERTY TO THE EXTENT PERMITTED BY LAW.

    5. END USER ACKNOWLEDGEMENT & COMPLIANCE

    • 5.1 By accepting, opening, or using the Products, the End User (Purchaser or its downstream recipient) agrees to be irrevocably bound by all terms herein.
    • 5.2 End User explicitly acknowledges the Products are NOT FOR HUMAN ADMINISTRATION and agrees not to use them in any in vivo human application, directly or indirectly.
    • 5.3 End Users unwilling to accept these terms must immediately: (a) cease all use; (b) notify ACRO or their supplier; and (c) return the unopened, unused Products.
    • 5.4 ACRO reserves the right to audit End User's compliance with these restrictions upon reasonable notice.

    ACRO has the right, at its sole discretion, to modify, add or remove any terms herein without notice to Purchaser and/or End User. Any changes to these terms are effective immediately following the updating of such changes on ACRO’s website or published specifications or product-related documents.

Recent Advances

 
Drug Development Progress
  • English Name:

    Interleukin-15

  • Category:

  • Approved Drugs:

    0 Details

  • Drugs in Clinical Trials:

    29 Details

  • Highest Development Stage:

    Phase 2 Clinical

Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background
  • Important Statement